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Summary
Inducible hepatic porphyrias are inherited genetic dis-
orders of enzymes of heme biosynthesis. The main clin-
ical manifestations are acute attacks of neuropsy-
chiatric symptoms frequently precipitated by drugs,
hormones, or fasting, associated with increased uri-
nary excretion of -aminolevulinic acid (ALA). Acute
attacks are treated by heme infusion and glucose ad-
ministration, but the mechanisms underlying the pre-
cipitating effects of fasting and the beneficial effects
of glucose are unknown. We show that the rate-limit-
ing enzyme in hepatic heme biosynthesis, 5-amino-
levulinate synthase (ALAS-1), is regulated by the per-
oxisome proliferator-activated receptor  coactivator
1 (PGC-1). Elevation of PGC-1 in mice via adeno-
viral vectors increases the levels of heme precursors
in vivo as observed in acute attacks. The induction
of ALAS-1 by fasting is lost in liver-specific PGC-1
knockout animals, as is the ability of porphyrogenic
drugs to dysregulate heme biosynthesis. These data
show that PGC-1 links nutritional status to heme
biosynthesis and acute hepatic porphyria.
Introduction
The heme biosynthetic pathway in eukaryotic cells is
comprised of eight enzymatic steps; the first and the
last three enzymes are located in the mitochondria,
while the rest are in the cytoplasm (Figure 1A). Eighty
to ninety percent of total heme in mammals is synthe-
sized in erythroid cells for incorporation into hemoglo-
bin. Regulation of heme biosynthesis in these cells in-
volves the erythroid-specific aminolevulinate synthase
(ALAS) gene ALAS-2. In contrast, the housekeeping
ALAS gene ALAS-1, also called ALAS-N or ALAS-H, is
ubiquitously expressed, given that all nucleated cells
must synthesize heme for respiratory cytochromes. The
bulk of the nonerythroid-synthesized heme is produced
in the liver for various heme proteins, in particular*Correspondence: bruce_spiegelman@dfci.harvard.edu
3This paper is dedicated to the memory of our dear colleague and
friend, Stanley J. Korsmeyer.microsomal cytochromes P450. Because either a defi-
ciency or an excess of heme is toxic to the cell, hepatic
heme production has to be tightly controlled, mostly
via its rate-limiting step ALAS-1. Accordingly, hepatic
ALAS-1 is highly regulated in different contexts to en-
sure adequate levels of intracellular heme (May et al.,
1995). Inherited mutations in all genes encoding for
heme biosynthetic enzymes have been described, ex-
cept for ALAS-1, and the resulting diseases are referred
to as porphyrias (Elder, 1998). Depending on the spe-
cific enzymatic defect, different patterns of overpro-
duction, accumulation, and excretion of intermediates
of heme synthesis are observed.
The main clinical manifestations of porphyrias are in-
termittent attacks of neuropsychiatric dysfunction and/
or sensitivity of the skin to sunlight. The neuropsychiat-
ric syndrome occurs only in those porphyrias in which
there is intermittent induction of hepatic ALAS-1 and
consequent increased urinary excretion of δ-aminolev-
ulinic acid (ALA). Attacks are characteristically precipi-
tated by drugs such as barbiturates, fasting, and hor-
mones and result in abdominal pain, tachycardia,
peripheral motor neuropathies, psychosis, and other
mental disturbances (Elder, 1998; Thadani et al., 2000;
Thunell, 2000). Inducible hepatic porphyrias are caused
by rare defects in δ-aminolevulinic acid dehydratase
(ALAD), porphobilinogen deaminase (PBGD, also known
as hydroxymethylbilane synthase), coproporphyrinogen
oxidase, and protoporphyrinogen oxidase. The classical
names for the corresponding diseases are ALAD defi-
ciency, acute intermittent porphyria, hereditary copropor-
phyria, and variegate porphyria.
Although not definitively proven, historic personali-
ties thought to have suffered from porphyria include
King George III (Macalpine and Hunter, 1966), Friedrich
Wilhelm I of Prussia (Macalpine et al., 1968; Pierach
and Jennewein, 1999), and Vincent van Gogh (Bonkov-
sky et al., 1992; Loftus and Arnold, 1991). Thus, the
psychoses arising from their disease potentially influ-
enced the course of the American war for indepen-
dence and/or the creative genius of van Gogh. Acute
attacks of inducible hepatic porphyria are treated by
discontinuing exposure to the precipitating agents,
heme infusions, and high carbohydrate load. The car-
bohydrates are typically given as concentrated glucose
infusion. Heme directly represses its own biosynthesis
in a negative feedback loop (May et al., 1995). In con-
trast, the underlying mechanisms of the beneficial ef-
fects of carbohydrates are not understood.
Proliferator-activated receptor γ coactivator 1α (PGC-
1α) is a coactivator of nuclear receptors and other tran-
scription factors (Puigserver and Spiegelman, 2003).
PGC-1α controls mitochondrial biogenesis and oxida-
tive metabolism in many tissues, including brown adi-
pose tissue, skeletal muscle, heart, and liver (Lehman
et al., 2000; Puigserver et al., 1998; Wu et al., 1999;
Yoon et al., 2001). In the liver, PGC-1α is induced during
fasting, when the liver ceases using glucose as an en-
ergy supply and changes to the β-oxidation of fatty
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506Figure 1. ALAS-1 Expression Is Activated by PGC-1α in Hepatocytes and Liver In Vivo
(A) Heme biosynthesis pathway. ALA, 5-aminolevulinic acid; ALAD, ALA dehydratase; PBG, porphobilinogen; PBGD, PBG deaminase; HMB,
hydroxymethylbiline; Uro-P, uroporphyrinogen; Copro-P, coproporphyrinogen; Cpo, coproporphyrinogen oxidase; Proto-P, protoporphy-
rinogen.
(B) ALAS-1 and PGC-1α mRNAs are coinduced in fasting. Mice were fasted for 6 hr and 24 hr, respectively, and hepatic levels of PGC-1α
and ALAS-1 were compared to those of fed and refed animals by semiquantitative PCR.
(C and D) Adenoviral PGC-1α increases ALAS-1 gene expression in cell culture. Fao rat hepatoma cells (C) and mouse primary hepatocytes
(D) were infected with adenovirus encoding GFP or PGC-1α, respectively, and relative mRNA levels of PGC-1α, glucose-6-phosphatase
(Glc6P), and ALAS-1 were determined by semiquantitative PCR 24 hr after infection.
(E) PGC-1α induces ALAS-1 transcript levels in vivo. Male Wistar rats were tail-vein injected with adenovirus encoding for GFP and PGC-1α,
respectively. Five days postinjection, animals were sacrificed, and hepatic mRNAs were analyzed for changes in expression using semiquanti-
tative PCR. Data in (B)–(E) are represented as mean ± standard deviation.acids. This increase in fatty-acid β-oxidation and eleva-
tion of hepatic gluconeogenesis are both under control
of PGC-1α (Herzig et al., 2001; Yoon et al., 2001).
Thus, because of the key role of PGC-1α in liver en-
ergy homeostasis and the finding that many PGC-1α
t
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aargets are heme proteins, we investigated the role of
GC-1α in the regulation of hepatic heme biosynthesis
y nutrition. We found that PGC-1α is an important fac-
or controlling the expression of ALAS-1 in the fasted
nd fed liver. Moreover, we showed that hepatic PGC-
Regulation of Heme Biosynthesis by PGC-1α
5071α is a major determinant of the severity of acute
porphyric attacks in mouse models of chemical por-
phyria.
Results
Hepatic PGC-1 and ALAS-1 Are Coregulated
in Fasting and Feeding
Since fasting can be a powerful stimulus to induce an
acute porphyric attack and the liver is central to the fast-
ing response in mammals, the metabolic status of the
liver should be crucial for the regulation of heme biosyn-
thesis. The transcriptional coactivator PGC-1α has been
described as a key factor in the control of hepatic gluco-
neogenesis in the fasted liver (Herzig et al., 2001; Yoon
et al., 2001). Interestingly, ALAS-1 and PGC-1α are cor-
egulated in fasted mice, with increased mRNA levels
(Figure 1B). To test the relationship between the regula-
tion of these two genes, Fao rat hepatoma cells, mouse
primary hepatocytes, and rat liver in vivo were infected
with adenovirus expressing PGC-1α. In all of these sys-
tems, ectopic expression of PGC-1α increased ALAS-1
transcript levels in a manner similar to that of glucose-
6-phosphatase (Glc6P), a PGC-1α target gene involved
in gluconeogenesis (Yoon et al., 2001) (Figures 1C–1E).
In contrast to ALAS-1, none of the other seven genes
of the heme biosynthetic pathway were induced by
PGC-1α in rat liver (Figure 1E).
Insulin and Glucagon Regulation of ALAS-1
Involves PGC-1
Regulation of ALAS-1 in fasting and feeding is medi-
ated by the counterregulatory hormones insulin and
glucagon (Scassa et al., 1998; Varone et al., 1999). Insu-
lin treatment of primary mouse hepatocytes reduces
basal levels of ALAS-1 mRNA (Figure 2A). Furthermore,Figure 2. ALAS-1 Expression Is Regulated by
PGC-1α and Insulin
(A) Insulin represses PGC-1α-mediated in-
duction of ALAS-1. H2.35 SV-40-transformed
hepatocyte cells were infected with adenovi-
ral GFP and PGC-1α for 24 hr and subse-
quently treated with vehicle (PBS) or 10 nM
insulin for 12 hr before relative ALAS-1, cyto-
chrome c, and PGC-1α mRNA levels were
determined. *p < 0.05 between vehicle- and
insulin-treated cells.
(B) ALAS-1 induction by dexamethasone and
forskolin is partially dependent on PGC-1α.
Mouse primary hepatocyte cultures were
established from wild-type and PGC-1α total
knockout animals. These cells were subse-
quently treated with dexamethasone (Dex, 1
M) and forskolin (Forsk, 0.2 M) for 3 hr,
and relative mRNA levels were determined
by semiquantitative PCR. Data in (A) and (B)
are represented as mean ± standard devia-
tion. *p < 0.05 between wild-type and knock-
out cells in Student’s t test.PGC-1α-induced ALAS-1 transcript levels are reduced
by insulin, suggesting that PGC-1α is in the pathway
of the insulin regulation of ALAS-1 (Figure 2A). Primary
hepatocytes from wild-type and PGC-1α knockout
mice (Lin et al., 2004) were used to elucidate the func-
tion of PGC-1α in the ALAS-1 induction in fasting, with
dexamethasone and forskolin representing the effects
of glucocorticoids and glucagon that are elevated when
blood glucose levels are low. Induction of ALAS-1
mRNA by these agents was reduced in the PGC-1α
knockout hepatocytes as compared to wild-type cells
(Figure 2B). Similarly, the response of the gluconeogenic
genes phosphoenolpyruvate carboxykinase (PEPCK) and
Glc6P to these hormones was blunted. These findings
imply that PGC-1α is involved in the fasting/feeding
regulation of all three genes.
Insulin Repression of ALAS-1 Is Mediated
by FOXO1 and PGC-1
In the ALAS-1 promoter, two binding sites for the
nuclear respiratory factor-1 (NRF-1) have been iden-
tified (Braidotti et al., 1993). NRF-1 is a transcription
factor that increases expression of nuclear-encoded
mitochondrial genes (Virbasius and Scarpulla, 1994)
and is known to be potently coactivated by PGC-1α
(Wu et al., 1999). Thus, NRF-1 is a potential binding
partner by which PGC-1α controls ALAS-1 expression.
In addition to the NRF-1 site, an insulin-responsive ele-
ment (IRE) has been defined in the ALAS-1 promoter
(Scassa et al., 2001, 2004), but the identity of transcrip-
tion factors binding to this element has remained elu-
sive (Figure 3A).
Chromatin immunoprecipitation assays in mouse
hepatoma cells illustrate that PGC-1α is recruited to
both the NRF-1 and the IRE regions (Figure 3B). More-
over, PGC-1α recruitment to the IRE region is sensitive
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508Figure 3. PGC-1α Regulates ALAS-1 Expression via NRF-1 and
FOXO1
(A) Structure of the ALAS-1 promoter.
(B) PGC-1α binds to the NRF-1 and the IRE sites on the ALAS-1
promoter. H2.35 cells were infected with adenoviral GFP or FLAG-
tagged PGC-1α. Cells were treated with 10 nM insulin for 12 hr
before cells were harvested and chromatin immunoprecipitation
was performed using an anti-FLAG antibody.
(C) PGC-1α coactivates FOXO1 on the ALAS-1 promoter. H.35 cells
were transfected with ALAS-1-promoter construct and expression
plasmids for FOXO1, HNF3α (FOXA1), HNF3β (FOXA2), and PGC-
1α. After transfection, cells were treated with 10 nM insulin for 12
hr before reporter-gene levels were determined. Data are repre-
sented as mean ± standard deviation.
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cto insulin, in contrast to PGC-1α binding to the NRF-1
site (Figure 3B). Sequence comparison of the ALAS-1
IRE to those of the gluconeogenic genes PEPCK and
Glc6P revealed high sequence conservation between
these sites. In the flanking regions of the gluconeogenic
genes, PGC-1α binds to FOXO1 at these elements. Af-
ter insulin exposure, FOXO1 is phosphorylated, its bind-
ing to PGC-1α disrupted, and, subsequently, FOXO1 is
exported from the nucleus (Puigserver et al., 2003).
Thus, FOXO1 is a plausible candidate to bind to the
ALAS-1 promoter.
Recently, Scassa and coworkers described the hepa-
tocyte nuclear factor 3β (HNF3β, alternatively called
FOXA2) to bind to sites adjacent to the ALAS-1 IRE
(Scassa et al., 2004) (Figure 3A). They found that integ-
rity of the IRE and not of the HNF3β sites is obligatory
for insulin regulation of ALAS-1 and that the regulation
of ALAS-1 by HNF3β cannot account for the repression
of ALAS-1 by insulin (Scassa et al., 2004). We thus
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cested the ability of PGC-1α to coactivate the different
orkhead box family members FOXO1, hepatocyte
uclear factor 3α (HNF3α, FOXA1), and HNF3β on the
LAS-1 promoter. As described by Scassa et al.,
NF3β increased reporter-gene levels controlled by the
LAS-1 promoter, whereas HNF3α had no effect (Figure
C). However, of the three transcription factors, PGC-
α only coactivated FOXO1 in this context. In addition,
erely the FOXO1-PGC-1α-mediated induction of the
LAS-1 promoter was repressed by insulin (Figure 3C).
To further characterize the role for FOXO1 in the regu-
ation of the ALAS-1 promoter, we showed direct physi-
al interaction of FOXO1 with the DNA probes contain-
ng the ALAS-1 IRE (Figure 4A, lanes 4–7) and NRF-1
ith the NRF-1 site (Figure 4A, lanes 1–3) in electropho-
etic mobility shift assays. Site-directed mutagenesis of
he FOXO1 site abolished binding of FOXO1 to this ele-
ent (Figure 4A, lanes 3 and 7, respectively). The speci-
icity of the FOXO1-IRE complex was confirmed by using
n anti-FOXO1 antibody that resulted in a supershift (Fig-
re 4A, lane 6). Functionally, PGC-1α coactivates both
RF-1 and FOXO1 in reporter-gene assays using the
LAS-1 promoter in mouse H2.35 SV-40-transformed
epatocytes (Figure 4B). Mutagenesis of the NRF-1 or
he IRE sites reduced the ability of PGC-1α to augment
he activity from the ALAS-1 promoter stimulated by
RF-1 and FOXO1, respectively. Moreover, an ALAS-1-
romoter allele with a combined mutation of both the
RF-1 and IRE sites is completely insensitive to PGC-
α, strongly suggesting that NRF-1 and FOXO1 are the
ajor binding partners of PGC-1α in the ALAS-1 pro-
oter.
As shown in Figure 4C, insulin represses induction of
LAS-1-promoter-driven reporter-gene expression by
ither FOXO1 alone or in combination with PGC-1α. In
ontrast, a nonphosphorylatable mutant of FOXO1 with
hree alanines in place of the serine/threonine residues
argeted by Akt kinase (termed FOXO1 3A) prevented
epression by insulin. Similarly, insulin is unable to in-
ibit PGC-1α coactivation of FOXO1 3A. This suggests
hat the insulin repression of the ALAS-1 promoter is
ontrolled by the FOXO1-PGC-1α interaction.
iver-Specific PGC-1 Knockout Animals Have
Blunted Induction of ALAS-1 in Fasting
o investigate whether PGC-1α is a key mediator of the
etabolic regulation of ALAS-1 in an in vivo setting, we
irst examined animals with a total knockout of PGC-1α
Lin et al., 2004) under fasting and feeding conditions.
nfortunately, regulation of ALAS-1 is masked by sys-
emic effects of the whole-body knockout of PGC-1α,
imilar to what has previously been described for the
luconeogenic genes (Lin et al., 2004): ALAS-1 mRNA
s constitutively induced to fasted levels in the total
nockout animals, even in the fed state (Figure 5A). It is
nclear whether the same compensatory mechanisms
elevation of C/EBPβ) account for the constitutive ex-
ression of the gluconeogenic genes and ALAS-1 (Lin
t al., 2004). Thus, in order to dissect systemic effects
f the total knockout from the liver phenotype, we had
o generate liver-specific PGC-1α knockout animals by
rossing mice with a floxed PGC-1α allele to transgenic
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509Figure 4. FOXO1-PGC-1α Mediate the Re-
pression of the ALAS-1 Promoter by Insulin
(A) FOXO1 binds to the ALAS-1 promoter.
Electrophoretic mobility shift assays were per-
formed using radiolabeled wild-type and mu-
tated ALAS-1 promoter as probe together
with in vitro-transcribed/translated NRF-1
and FOXO1, respectively.
(B) PGC-1α induction of the ALAS-1 promoter
is mediated by NRF-1 and FOXO1. H2.35
cells were transfected with wild-type and
ALAS-1-promoter constructs with mutations
in the NRF-1 and the IRE sites together with
expression plasmids for PGC-1α, NRF-1,
and FOXO1. Reporter-gene levels were de-
termined 16 hr after transfection.
(C) Insulin regulation of the ALAS-1 promoter
is inhibited by a mutant FOXO1 allele. H2.35
cells were transfected with a reporter-gene
plasmid driven by the wild-type ALAS-1
promoter together with expression plasmids
for PGC-1α, FOXO1, and FOXO1 3A, a
FOXO1 allele that is not phosphorylated by
insulin signaling. After transfection, cells
were treated with 10 nM insulin for 12 hr be-
fore reporter-gene levels were determined.
Data in (B) and (C) are represented as mean ±
standard deviation. *p < 0.05 between vehi-
cle- and insulin-treated cells in Student’s t
test.animals expressing cre recombinase under the control
of the albumin promoter (Figure 5B). Tissue-specific
ablation of PGC-1α in the liver was verified by mRNA
analysis (Figure 5C). PGC-1α levels in the heart, skele-
tal muscle (SKM), and brown adipose tissue (BAT) were
unaltered. Moreover, liver-specific knockout of PGC-1α
did not change the expression of the closely related
family member PGC-1β in liver, heart, skeletal muscle,
or brown adipose tissue.
In these mice, basal levels of ALAS-1, PEPCK, and
Glc6P were not elevated, as was seen in the total knock-
out (Figure 5D). Indeed, ALAS-1 basal expression was
significantly lower in the liver-specific PGC-1α knock-
out as compared to wild-type animals. Moreover, the
induction of ALAS-1 and the gluconeogenic genes after
16 hr of fasting was severely blunted in the liver-spe-cific knockout animals compared to wild-type mice
(Figure 5D). These findings indicate a requirement for
PGC-1α in the fasting/feeding regulation of the gluco-
neogenic genes and, furthermore, imply a key role for
PGC-1α in the dietary control of ALAS-1 transcription.
Patients suffering from porphyric attacks are given a
high carbohydrate load. Thus, in addition to refeeding,
fasted mice were i.p. injected with a bolus of glucose
(1 g/kg) or glucose (1 g/kg) and insulin (1.0 U/kg) 30
min, 60 min, or 120 min before mice were sacrificed
and hepatic PGC-1α and ALAS-1 mRNA levels were de-
termined (Figure 5E). Glucose loading reduces ALAS-1
transcript levels 30 min after injection. The combination
of glucose and insulin is even more potent in inhibiting
fasting-mediated induction of PGC-1α and ALAS-1,
supporting the hypothesis that at least part of the bene-
Cell
510Figure 5. Fasting-Mediated Induction of ALAS-1 Is Drastically Reduced in a Liver-Specific PGC-1α Knockout Model
(A) Hepatic ALAS-1 is constitutively increased in fasting and feeding in PGC-1α total knockout mice. PGC-1α total knockout animals were
fasted for 12 hr before relative mRNA levels for PGC-1α, ALAS-1, and phosphoenolpyruvate carboxykinase (PEPCK) were determined.
(B) Generation of liver-specific PGC-1α knockout animals. Mice with a floxed PGC-1α allele were crossed with animals that transgenically
express cre recombinase under the control of the albumin promoter.
(C) Hepatic expression of PGC-1α is absent in the liver-specific knockout animals. Different tissues were harvested from wild-type and
knockout mice, and relative PGC-1α and PGC-1β levels were determined by semiquantitative PCR. SKM, skeletal muscle; BAT, brown adi-
pose tissue.
(D) Absence of PGC-1α abolishes ALAS-1 induction in the liver by fasting. Wild-type and liver-specific PGC-1α knockout mice were fasted
for 12 hr, and relative transcript levels for PGC-1α, ALAS-1, PEPCK, and glucose-6-phosphatase (Glc6P) were determined by semiquantita-
tive PCR.
(E) Glucose reverses fasting-mediated induction of PGC-1α and ALAS-1. Wild-type and liver-specific PGC-1α knockout animals were fasted
for 6 hr and subsequently injected with vehicle, glucose, or glucose and insulin. After 30, 60, or 120 min, respectively, mice were sacrificed,
livers were harvested, and relative PGC-1α and ALAS-1 expression levels were determined.
(F) Phenobarbital induces ALAS-1 independent of PGC-1α. Wild-type and liver-specific PGC-1α knockout animals were injected i.p. with
vehicle (saline) or phenobarbital (100 mg/kg). Sixteen hours after injection, livers were harvested, and relative mRNA levels of PGC-1α, ALAS-1,
and cytochrome P450 2b10 and 3a11 (Cyp2b10 and Cyp3a11, respectively) were determined by semiquantitative PCR. Data in (A) and (C)–
(F) are represented as mean ± standard deviation. *p < 0.05 between wild-type and knockout animals in Student’s t test.ficial effect of glucose in acute porphyric attacks is me-
diated by the glucose-triggered increase of plasma in-
sulin. ALAS-1 mRNA is not regulated by fasting in the
knockout mice, and, thus, no effect of glucose and/or
insulin on ALAS-1 transcript levels could be observed.
Taken together, these data strongly suggest that
PGC-1α may be involved in fasting-induced acute
porphyric attacks. Apart from fasting, certain drugs
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ttrongly regulate ALAS-1 levels and, therefore, are able
o precipitate porphyric attacks (Elder et al., 1997; Tha-
ani et al., 2000). There are two different classes of
hemicals that perturb heme homeostasis: first, drugs
hat increase heme biosynthesis by inducing ALAS-1,
nd second, compounds that block different steps of
eme biosynthesis and thus generate various heme in-
ermediates. Representative for the first class of drugs,
Regulation of Heme Biosynthesis by PGC-1α
511Figure 6. Ectopic Expression of PGC-1α Elicits an Acute Porphyric Attack
(A) Lead (Pb) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) inhibit heme biosynthesis at different steps.
(B and C) Ectopic PGC-1α expression increases ALAS-1 levels and heme intermediates. Adenoviral GFP or PGC-1α was injected into the tail
veins of wild-type animals, which were fasted 4 days later and treated with corn oil and DDC (10 mg/kg) for 24 hr. Transcript levels of PGC-
1α (B) and ALAS-1 (C) were determined after the mice were sacrificed 24 hr later.
(D and E) Plasma of tail-vein-injected animals was collected, and 5-aminolevulinic acid (ALA) levels (D) and porphobilinogen (PBG) levels (E)
were determined. Data in (B)–(E) are represented as mean ± standard deviation. *p < 0.05 between GFP- and PGC-1α-infected animals in
Student’s t test.we chose the barbiturate phenobarbital (PB), a classi-
cal drug that precipitates porphyric attacks in patients.
As shown in Figure 5F, no significant difference in PB
induction of ALAS-1 and the prototypical PB-target
genes cytochromes P450 Cyp2b10 and Cyp3a11, two
microsomal cytochromes P450 with a heme moiety as
prosthetic group, was observed between wild-type and
liver-specific PGC-1α knockout animals. These data in-
dicate that the role of PGC-1α in ALAS-1 regulation
does not extend universally to all other mechanisms,
such as the induction by barbiturate drugs (Fraser et
al., 2002, 2003; Podvinec et al., 2004).
Elevated Expression of PGC-1 Causes Acute
Attacks in Chemical Porphyria
The consequence of ALAS-1 regulation by PGC-1α in
fasting and feeding for acute porphyric attacks wassubsequently tested using proporphyrogenic drugs
that are known to function by disruption of the pathway
of hepatic heme biosynthesis. Two members of this class
of chemicals are lead (Pb) and 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC) (Figure 6A). Lead intoxica-
tion produces symptoms resembling those of acute
hepatic porphyria (May et al., 1995). Because of its abil-
ity to replace other ions such as zinc and to block
thiol groups, lead inhibits several enzymes in heme
biosynthesis, most importantly ALAD. Another drug
widely used to induce porphyria in systems that lack
the genetic predisposition for this disorder, DDC,
causes accumulation of N-methyl protoporphyrin, a po-
tent inhibitor of ferrochelatase (De Matteis et al., 1973).
In gain-of-function experiments, mice were injected i.v.
with adenoviral GFP and PGC-1α. These animals were
subsequently fasted and treated with vehicle (corn oil)
or DDC for 24 hr. DDC did not change adenoviral ex-
Cell
512pression of PGC-1α mRNA (Figure 6B). In contrast,
ALAS-1 transcript levels were elevated 10-fold in ani-
mals that received both PGC-1α adenovirus and DDC
(Figure 6C). This high induction of ALAS-1 was re-
flected in the dramatically increased levels of the heme
precursors 5-ALA and PBG in their plasma (Figures 6D
and 6E), to 9 M and 27 M, respectively. Importantly,
these are levels that are seen in acute attacks in mouse
models of porphyria. Thus, in wild-type animals with
chemical porphyria, elevation of PGC-1α expression in
the liver results in accumulation of heme precursors
comparable to that classically observed in drug-precip-
itated acute attacks in genetic mouse models of por-
phyria (Lindberg et al., 1996, 1999).
Liver-Specific PGC-1 Knockout Animals Are
Protected from Chemical Porphyria
The requirement for PGC-1α in fasting-induced por-
phyria was tested in the liver-specific PGC-1α knockout
animals. In fasted wild-type animals treated with lead
chloride and DDC for 24 hr, increased ALAS-1 mRNA
levels were observed as compared to treatment with
their vehicles saline and corn oil, respectively (Figure
7A). In contrast, neither lead chloride nor DDC changed
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AFigure 7. Liver-Specific PGC-1α Knockout Animals Are Protected
from Chemical Porphyria
Lack of increase in ALAS-1 mRNA and heme biosynthesis interme-
diates in liver-specific PGC-1α knockout animals. Fasted wild-type
and knockout animals were i.p. injected with saline and lead chlo-
ride (PbCl2, 20 mg/kg) or corn oil and DDC (10 mg/kg) for 24 hr.
After animals were sacrificed, ALAS-1 mRNA levels (A), ALA plasma
levels (B), and PBG plasma levels (C) were determined. Data are
represented as mean ± standard deviation. *p < 0.05 between wild-
type and knockout animals in Student’s t test.
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vndogenous PGC-1α levels (data not shown). As a con-
equence of the ALAS-1 induction and the chemical
lock in the biosynthetic pathway, 5-ALA accumulates
n plasma after lead and DDC treatment (Figure 7B).
ince lead and DDC inhibit heme biosynthesis at dif-
erent steps (Figure 6A), only DDC elevates PBG levels
Figure 7C). Thus, as reported, blocking of heme bio-
ynthesis with porphyrogenic drugs results in a state of
atent porphyria in wild-type mice, comparable to the
tatus of patients between attacks, which is charac-
erized by moderately elevated levels of 5-ALA and
BG (De Matteis, 1973). In an actual acute attack,
-ALA and PBG levels rise to those observed in the
ain-of-function experiment shown in Figure 6D and
E. Strikingly, lead and DDC completely fail to induce
ither ALAS-1 mRNA (Figure 7A) or plasma 5-ALA (Fig-
re 7B) or PBG levels (Figure 7C) in the liver-specific
GC-1α knockout mouse. These data indicate that
GC-1α is absolutely required for animals treated with
orphyrogenic drugs to enter a state of latent por-
hyria.
iscussion
hile the biochemical consequences of mutations in
he heme biosynthetic pathway are well known, the mo-
ecular mechanisms underlying the nutritional regula-
ion of hepatic porphyrias have been poorly under-
tood. Specifically, questions regarding how fasting
an precipitate porphyric attacks and why glucose infu-
ions provide therapeutic benefit have remained unan-
wered. The results presented here provide a clear-cut
echanism, deduced from biochemical and genetic
vidence: the transcriptional coactivator PGC-1α is in-
uced in the liver in fasting and potently turns on ex-
ression of the ALAS-1 gene in hepatocytes and in liver
n vivo. The induction of PGC-1α in fasting has pre-
iously been shown to be a consequence of glucagon
ction and the transcription factor cAMP element bind-
ng protein (CREB), which binds directly to the PGC-1α
romoter (Herzig et al., 2001). In addition, CREB can
lso directly activate the ALAS-1 promoter (Varone et
l., 1999).
PGC-1α activates the ALAS-1 promoter by coactivat-
ng NRF-1 and FOXO1, both of which directly bind to
he ALAS-1 promoter (Figure 6). The ability of PGC-1α
o positively regulate the ALAS-1 gene and the require-
ent for PGC-1α in the fasting induction of ALAS-1 to-
ether provide a direct explanation for how fasting can
rovoke an acute attack in an individual with a mutation
n the pathway of heme biosynthesis that results in he-
atic porphyria. Indeed, adenoviral expression of PGC-
α in mice with chemical inhibition of enzymes of heme
iosynthesis results in significantly elevated porphyrin
recursor levels reminiscent of acute porphyric attacks.
n contrast, the excess production of heme intermedi-
tes by porphyrogenic drugs is lost in the liver-specific
GC-1α knockout.
The therapeutic effect of glucose on acute hepatic
orphyria is well documented (Robert et al., 1994).
oreover, it has been established that ALAS-1 tran-
cription is inhibited by the insulin pathway involving
kt (Kappas et al., 1995; Scassa et al., 2001). Our data
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513for the first time illustrate likely mechanisms by which
glucose and the subsequent elevation of insulin, which
occurs in vivo in response to glucose, can ameliorate
an acute porphyric attack. First, increased levels of in-
sulin will certainly blunt the expression of PGC-1α. Glu-
cagon is important in PGC-1α expression, and rising
blood glucose dampens glucagon secretion (Herzig et
al., 2001; Yoon et al., 2001). Second, insulin has been
shown to activate the protein kinase Akt in the liver, and
Akt in turn phosphorylates FOXO1 (Brunet et al., 1999;
Nakae et al., 2001). Phosphorylation of FOXO1 results
in disruption of its binding to PGC-1α and its export
from the nucleus (Puigserver et al., 2003), thus inhibit-
ing PGC-1α action. Increased blood glucose levels
would therefore be expected to alter the PGC-1α mod-
ulation of ALAS-1 gene expression by two related but
independent mechanisms. This hypothesis is supported
by the reduced ALAS-1 mRNA levels in fed mice that
have constitutively elevated PGC-1α levels after tail-
vein injection of adenoviral vectors (see Figure S1 in
the Supplemental Data available with this article on-
line). Thus, despite high PGC-1α levels, ALAS-1 mRNA
transcription can be reduced by insulin-triggered nuclear
exclusion of FOXO1. Moreover, like insulin, glucose has
been shown to have an inhibitory effect on ALAS-1
transcription in cell culture (Canepa et al., 1984; Giger
and Meyer, 1981). Under our experimental conditions,
glucose alone did not significantly repress basal or
PGC-1α-induced ALAS-1 mRNA levels (Figure S2).
However, insulin and glucose together were more effi-
cient than insulin in reducing ALAS-1 expression. Thus, in
addition to its effect on insulin secretion, glucose could
directly affect ALAS-1 transcription. Candidate pathways
include the AMP-activated protein kinase (AMPK), pro-
tein phosphatase 2A (PP2A), and carbohydrate-response
element binding protein (ChREBP) (Kawaguchi et al.,
2002; Yamashita et al., 2001), although an effect of this
signaling cascade on ALAS-1 remains to be shown.
Agents that elevate hepatic PGC-1α levels are there-
fore potentially dangerous for patients with hepatic
porphyrias. Accordingly, drugs and foods that induce
PGC-1α in the liver should be avoided. Unfortunately,
because of the therapeutic high carbohydrate intake,
patients with hepatic porphyrias are prone to weight
gain. Losing excess weight is very difficult for some of
these patients because of fasting-induced acute at-
tacks. Hopefully, our findings described here might lead
to the development of more specific treatments for
these patients.
Experimental Procedures
RNA Isolation and Analysis
Total RNA was isolated from liver or cultured cells using the Trizol
reagent (Invitrogen) according to the manufacturer’s protocol. For
semiquantitative real-time PCR analysis, 1 g of total RNA was
treated with RNase-free DNase and subsequently reverse tran-
scribed with random hexamer primers (Roche Applied Science).
Relative mRNA abundance normalized to 18S rRNA levels was de-
termined with the Ct method after amplification using a iCycler
iQ real-time PCR detection system (Bio-Rad) and SYBRGreen (Bio-
Rad). Data are represented as mean ± standard deviation. Signifi-
cance is defined as p < 0.05 in Student’s t test.
Animal Experiments
All animal experiments were performed according to procedures
approved by the Institutional Animal Care and Use Committee. Ani-mals were fed standard rodent chow and housed in a controlled
environment with 12 hr light and dark cycles. For fasting experi-
ments, mice were deprived of food for the indicated amount of time
before animals were sacrificed. Drugs (phenobarbital, 100 mg/kg;
PbCl2, 20 mg/kg; DDC, 10 mg/kg) were injected i.p., and livers and
blood were harvested after 16 or 24 hr. All groups consisted of at
least three to six mice. Glucose (1 g/kg) and insulin (1.0 U/kg) were
injected i.p. into mice that were fasted for 6 hr. Data are repre-
sented as mean ± standard deviation. Significance is defined as
p < 0.05 in Student’s t test.
Generation of Liver-Specific PGC-1 Knockout Animals
Generation of animals with floxed PGC-1α alleles has been de-
scribed (Lin et al., 2004). These mice were crossed with mice that
transgenically express cre recombinase under the control of the rat
albumin promoter (Jackson Laboratory, strain B6.Cg-Tg(Alb-cre)
21MGn/J) to obtain liver-specific PGC-1α knockout mice.
Adenoviral Infection
Cultured cells were infected with adenovirus as published (Yoon et
al., 2001). Twenty-four to forty-eight hours after infection, cells were
harvested. Male Wistar rats were transduced with purified adenovi-
rus via tail-vein injection as described (Yoon et al., 2001). Mice were
tail-vein injected with 0.2 OD of cesium-chloride-gradient-purified
adenovirus. Five days later, mice were sacrificed and livers and
plasma were harvested. Data are represented as mean ± standard
deviation. Significance is defined as p < 0.05 in Student’s t test.
Cell Culture (Fao, H2.35, Primary Hepatocytes), Transfection,
and Reporter-Gene Assays
Fao rat hepatoma cells were cultured in RPMI medium with 10%
fetal calf serum. H2.35 mouse SV-40-transformed hepatocyte cells
were kept in DMEM supplemented with 4% fetal calf serum and
0.2 M dexamethasone. Primary mouse hepatocytes were isolated
and cultured as described (Lin et al., 2004). Cells were transfected
using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol. For reporter-gene assays, cells were harvested 48 hr
after transfection. Luciferase levels were determined and normal-
ized to β-galactosidase expression as published (Iniguez-Lluhi et
al., 1997). For treatment with glucose (33 mM), cells were cultured
in glucose-free DMEM (Mediatech). Data are represented as mean ±
standard deviation. Significance is defined as p < 0.05 in Student’s
t test.
Cloning of Promoter Constructs and Site-Directed Mutagenesis
The rat ALAS-1 promoter (Braidotti et al., 1993) was amplified by
PCR and cloned into the pGL3 basic luciferase reporter-gene vec-
tor (Promega). Site-directed mutagenesis was performed using
overlapping primers. All constructs were verified by sequencing.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays were performed as described
(Handschin et al., 2003). Briefly, wild-type and mutant ALAS-1-pro-
moter fragments were radiolabeled and used as probes together
with in vitro-transcribed/translated proteins. Protein-DNA com-
plexes were subsequently separated by polyacrylamide gel elec-
trophoresis. FOXO1 antibody was purchased from Santa Cruz Bio-
technology.
Chromatin Immunoprecipitation
Experiments were performed using the Chromatin Immunoprecipi-
tation (ChIP) Assay Kit (Upstate) following the manufacturer’s pro-
tocol. H2.35 cells were infected with adenoviral GFP and FLAG-
tagged PGC-1α for 24 hr and treated with vehicle or 10 nM insulin
for 12 hr before cells were harvested, DNA-protein complexes
crosslinked, and immunoprecipitation reactions performed using
anti-FLAG beads (Sigma). After reverse crosslinking, DNA was puri-
fied by phenol/chloroform extraction and ethanol precipitation, and
relative levels were subsequently analyzed by PCR.
Determination of ALA and PBG Plasma Levels
When animals were sacrificed, blood was harvested by cardiac
puncture. Blood plasma was purified by centrifugation in heparin
Cell
514tubes (Becton Dickinson) and treated as described (Mendez et al.,
1999). ALA and PBG levels in the plasma were subsequently ana-
lyzed by sequential ion-exchange chromatography using columns
from the ALA/PBG by Column Test Kit (Bio-Rad) using a modified
protocol (Davis and Andelman, 1967). PBG and ALA were absorbed
on anion- and cation-exchange resins, respectively. Following elu-
tion and conversion to pyrrole in the case of ALA, Ehrlich’s reagent
was added, and PBG and ALA levels were determined colorimet-
rically. Data are represented as mean ± standard deviation. Signifi-
cance is defined as p < 0.05 in Student’s t test.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/cgi/content/full/122/4/505/
DC1/.
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